Numab Therapeutics is a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer.
Numab designs and develops a new class of powerful therapeutics for the treatment of severe diseases.
Numab was co-founded in 2011 by David Urech, Oliver Middendorp, and Peter Lichtlen. The company is headquartered in Zurich, Zurich, Switzerland.
Numab is writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.
Numab's plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.
Numab's pipeline was created using its antibody discovery and engineering MATCH platform that produces highly potent and stable antibody Fv fragments, which can serve as the mono or multi-specific antibody-based therapies.
Numab is backed by 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co. and others. The company raised CHF 22M (approximately $22.6M) in a Series B round on Mar 09, 2020. This brings Numab's total funding to $37.6M to date.